Ofatumumab for the treatment of chronic lymphocytic leukemia.

Abstract

Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is different as it includes a short as well… (More)
DOI: 10.1586/17474086.2015.1037736

Topics

  • Presentations referencing similar topics